Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

© 2016 Macmillan Publishers Limited.
Familial hypercholesterolaemia, familial combined hyperlipidaemia (FCH) and elevated lipoprotein(a) are common, inherited disorders of apolipoprotein B metabolism that markedly accelerate the onset of atherosclerotic cardiovascular disease (ASCVD). These disorders are frequently encountered in clinical lipidology and need to be accurately identified and treated in both index patients and their family members, to prevent the development of premature ASCVD. The optimal screening strategies depend on the patterns of heritability for each condition. Established therapies are widely used along with lifestyle interventions to regulate levels of circulating lipoproteins. New therapeutic strategies are becoming available, and could supplement traditional approaches in the most severe cases, but their long-term cost-effectiveness and safety have yet to be confirmed. We review contemporary developments in the understanding, detection and care of these highly atherogenic disorders of apolipoprotein B metabolism.
Original languageEnglish
Pages (from-to)467-484
Number of pages18
JournalNature Reviews Endocrinology
Volume12
Issue number8
DOIs
Publication statusPublished - Aug 2016

Fingerprint

Apolipoproteins B
Cardiovascular Diseases
Familial Combined Hyperlipidemia
Hyperlipoproteinemia Type II
Lipoprotein(a)
Lipoproteins
Cost-Benefit Analysis
Life Style
Safety
Therapeutics

Cite this

@article{377c75c037df41788f3eb997b6498b46,
title = "Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism",
abstract = "{\circledC} 2016 Macmillan Publishers Limited.Familial hypercholesterolaemia, familial combined hyperlipidaemia (FCH) and elevated lipoprotein(a) are common, inherited disorders of apolipoprotein B metabolism that markedly accelerate the onset of atherosclerotic cardiovascular disease (ASCVD). These disorders are frequently encountered in clinical lipidology and need to be accurately identified and treated in both index patients and their family members, to prevent the development of premature ASCVD. The optimal screening strategies depend on the patterns of heritability for each condition. Established therapies are widely used along with lifestyle interventions to regulate levels of circulating lipoproteins. New therapeutic strategies are becoming available, and could supplement traditional approaches in the most severe cases, but their long-term cost-effectiveness and safety have yet to be confirmed. We review contemporary developments in the understanding, detection and care of these highly atherogenic disorders of apolipoprotein B metabolism.",
author = "Ellis, {Katrina L.} and Hooper, {Amanda J.} and Burnett, {John R.} and Watts, {Gerald F.}",
year = "2016",
month = "8",
doi = "10.1038/nrendo.2016.69",
language = "English",
volume = "12",
pages = "467--484",
journal = "Nature Reviews Endocrinology",
issn = "1745-8366",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism

AU - Ellis, Katrina L.

AU - Hooper, Amanda J.

AU - Burnett, John R.

AU - Watts, Gerald F.

PY - 2016/8

Y1 - 2016/8

N2 - © 2016 Macmillan Publishers Limited.Familial hypercholesterolaemia, familial combined hyperlipidaemia (FCH) and elevated lipoprotein(a) are common, inherited disorders of apolipoprotein B metabolism that markedly accelerate the onset of atherosclerotic cardiovascular disease (ASCVD). These disorders are frequently encountered in clinical lipidology and need to be accurately identified and treated in both index patients and their family members, to prevent the development of premature ASCVD. The optimal screening strategies depend on the patterns of heritability for each condition. Established therapies are widely used along with lifestyle interventions to regulate levels of circulating lipoproteins. New therapeutic strategies are becoming available, and could supplement traditional approaches in the most severe cases, but their long-term cost-effectiveness and safety have yet to be confirmed. We review contemporary developments in the understanding, detection and care of these highly atherogenic disorders of apolipoprotein B metabolism.

AB - © 2016 Macmillan Publishers Limited.Familial hypercholesterolaemia, familial combined hyperlipidaemia (FCH) and elevated lipoprotein(a) are common, inherited disorders of apolipoprotein B metabolism that markedly accelerate the onset of atherosclerotic cardiovascular disease (ASCVD). These disorders are frequently encountered in clinical lipidology and need to be accurately identified and treated in both index patients and their family members, to prevent the development of premature ASCVD. The optimal screening strategies depend on the patterns of heritability for each condition. Established therapies are widely used along with lifestyle interventions to regulate levels of circulating lipoproteins. New therapeutic strategies are becoming available, and could supplement traditional approaches in the most severe cases, but their long-term cost-effectiveness and safety have yet to be confirmed. We review contemporary developments in the understanding, detection and care of these highly atherogenic disorders of apolipoprotein B metabolism.

U2 - 10.1038/nrendo.2016.69

DO - 10.1038/nrendo.2016.69

M3 - Review article

VL - 12

SP - 467

EP - 484

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

SN - 1745-8366

IS - 8

ER -